Phase I study of APG-1387 in Hepatitis B patients.
Phase of Trial: Phase I
Latest Information Update: 26 Feb 2018
At a glance
- Drugs APG 1387 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions
- 26 Feb 2018 New trial record
- 13 Feb 2018 According to the Ascentage Pharma media release, China Food and Drug Administration (CFDA) has accepted the Investigational New Drug (IND) application for APG-1387 for the treatment of the Hepatitis B virus (HBV) infection.